Attached files

file filename
8-K - FORM 8-K - MCKESSON CORPd287717d8k.htm

Exhibit 99.1

LOGO

McKESSON REPORTS FISCAL 2012 THIRD-QUARTER RESULTS

 

 

Revenues of $30.8 billion for the third quarter, up 9%.

 

 

Third-quarter GAAP earnings per diluted share of $1.20.

 

 

Third-quarter Adjusted Earnings per diluted share of $1.40, up 9%.

 

 

Announced definitive agreement to acquire the independent banner and franchise businesses of Katz Group Canada Inc.

 

 

Board of Directors authorized an additional $650 million share repurchase program, bringing the total authorization to $1.5 billion.

 

 

Fiscal 2012 Outlook: Adjusted Earnings of $6.19 to $6.39 per diluted share.

 

SAN FRANCISCO, January 30, 2012 – McKesson Corporation (NYSE: MCK) today reported that revenues for the third quarter ended December 31, 2011 were up 9% to $30.8 billion compared to $28.2 billion a year ago. On the basis of U.S. generally accepted accounting principles (“GAAP”), third-quarter earnings per diluted share was $1.20 compared to $0.60 a year ago.

Third-quarter GAAP results included a pre-tax charge of $27 million ($15 million after-tax or six cents per diluted share), recorded in the Distribution Solutions segment, to increase an existing litigation reserve for claims against McKesson relating to First DataBank’s published drug reimbursement benchmarks, commonly referred to as Average Wholesale Prices (“AWP”). Last year’s third-quarter GAAP results also included a pre-tax AWP litigation charge of $189 million ($133 million after-tax or 52 cents per diluted share).

McKesson separately reports financial results on the basis of Adjusted Earnings in addition to GAAP. Adjusted Earnings is a non-GAAP financial measure defined as GAAP earnings from continuing operations, excluding acquisition-related expenses, amortization of acquisition-related intangible assets, and certain litigation reserve adjustments. A reconciliation of McKesson’s financial results determined in accordance with GAAP to Adjusted Earnings is provided in Schedules 2, 3 and 4 of the financial statement tables included with this release. Third-quarter Adjusted Earnings per diluted share was $1.40 compared to $1.28 a year ago.


For the first nine months of the fiscal year, McKesson generated cash from operations of $1.7 billion and ended the quarter with cash and cash equivalents of $4.2 billion. During the first nine months of the fiscal year, the company deployed $204 million for acquisitions, repurchased $650 million of common stock, and paid $146 million in dividends.

The Board of Directors authorized the repurchase of up to an additional $650 million of common stock, bringing the total authorization to approximately $1.5 billion.

“McKesson delivered another quarter of solid operating results, and I am pleased with our accomplishments during the first nine months of our fiscal year,” said John H. Hammergren, chairman and chief executive officer. “Our strong balance sheet and cash flow also provide us with significant opportunities to create shareholder value. Today, we announced a definitive agreement to purchase for approximately CAD $920 million the independent banner and franchise businesses of Katz Group Canada Inc., a privately-owned company that operates an integrated retail pharmacy network in Canada. We are excited about this acquisition which, combined with our increased share repurchase authorization, demonstrates our commitment to using a portfolio approach to deploy our significant cash balances. Based on our year-to-date progress, we continue to expect Adjusted Earnings between $6.19 and $6.39 per diluted share for the fiscal year ending March 31, 2012.”

Distribution Solutions revenues were up 9% in the third quarter, driven mainly by strong growth in U.S. pharmaceutical direct distribution and services revenues, reflecting market growth and our mix of business, as well as the acquisition of US Oncology.

Canadian revenues, on a constant currency basis, were down 3% for the quarter due in part to the impact of government imposed price reductions on generic drugs. Including an unfavorable currency impact of 1%, Canadian revenues were down 4% for the quarter. Medical-Surgical distribution revenues increased 2% for the quarter.

 

2


In the third quarter, Distribution Solutions gross profit improved due to the positive impact of the US Oncology acquisition.

Distribution Solutions GAAP operating profit was $510 million for the quarter and the GAAP operating margin was 1.70%. Adjusted operating profit was $572 million for the quarter and the adjusted operating margin was 1.91%.

Technology Solutions revenues were up 4% in the third quarter. GAAP operating profit was $69 million and the GAAP operating margin was 8.38%. Adjusted operating profit in the third quarter was $89 million and the adjusted operating margin was 10.81%. In the third quarter, we recorded a pre-tax product alignment charge of $42 million. This charge related to Technology Solutions’ strategy to converge core clinical and revenue cycle information technology solutions for the Horizon and Paragon® product lines onto Paragon’s Microsoft® platform over time.

Fiscal Year 2012 Outlook

McKesson expects Adjusted Earnings between $6.19 and $6.39 per diluted share for the fiscal year ending March 31, 2012, which excludes the following GAAP items:

 

 

Amortization of acquisition-related intangible assets of approximately 48 cents per diluted share in Fiscal 2012.

 

 

Acquisition-related expenses of approximately seven cents per diluted share in Fiscal 2012.

 

 

Litigation reserve adjustments of 37 cents per diluted share.

 

3


Risk Factors

Except for historical information contained in this press release, matters discussed may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These statements may be identified by their use of forward-looking terminology such as “believes”, “expects”, “anticipates”, “may”, “will”, “should”, “seeks”, “approximately”, “intends”, “plans”, “estimates” or the negative of these words or other comparable terminology. The discussion of financial trends, strategy, plans or intentions may also include forward-looking statements. It is not possible to predict or identify all such risks and uncertainties; however, the most significant of these risks and uncertainties are described in the company’s Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission and include, but are not limited to: material adverse resolution of pending legal proceedings; changes in the U.S. healthcare industry and regulatory environment; changes in the Canadian healthcare industry and regulatory environment; competition; substantial defaults in payment or a material reduction in purchases by, or the loss of, a large customer or group purchasing organization; the loss of government contracts as a result of compliance or funding challenges; public health issues in the U.S. or abroad; implementation delay, malfunction or failure of internal information systems; the adequacy of insurance to cover property loss or liability claims; the company’s failure to attract and retain customers for its software products and solutions due to integration and implementation challenges, or due to an inability to keep pace with technological advances; the company’s proprietary products and services may not be adequately protected, and its products and solutions may be found to infringe on the rights of others; system errors or failure of our technology products and solutions to conform to specifications; disaster or other event causing interruption of customer access to data residing in our service centers; the delay or extension of our sales or implementation cycles for external software products; changes in circumstances that could impair our goodwill or intangible

 

4


assets; foreign currency fluctuations or disruptions to our foreign operations; new or revised tax legislation or challenges to our tax positions; the company’s ability to successfully identify, consummate and integrate strategic acquisitions; general economic conditions, including changes in the financial markets that may affect the availability and cost of credit to the company, its customers or suppliers; and changes in accounting principles generally accepted in the United States of America. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.

The company has scheduled a conference call for 5 PM ET. The dial-in number for individuals wishing to participate on the call is 719-234-7317. Ana Schrank, vice president, Investor Relations, is the leader of the call, and the password to join the call is ‘McKesson’. A replay of this conference call will be available for five calendar days. The dial-in number for individuals wishing to listen to the replay is 888-203-1112 and the passcode is 9240566. A webcast of the conference call will also be available live and archived on the company’s Investor Relations website at www.mckesson.com/investors.

Shareholders are encouraged to review SEC filings and more information about McKesson, which are located on the company’s website.

 

5


About McKesson

McKesson Corporation, currently ranked 15th on the FORTUNE 500, is a healthcare services and information technology company dedicated to making the business of healthcare run better. We partner with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. For more information, visit http://www.mckesson.com.

###

Contact:

Ana Schrank, 415-983-7153 (Investors and Financial Media)

Ana.Schrank@McKesson.com

Kris Fortner, 415-983-8352 (General and Business Media)

Kris.Fortner@McKesson.com

 

6


Schedule 1

McKESSON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS — GAAP

(unaudited)

(in millions, except per share amounts)

 

     Quarter Ended December 31,            Nine Months Ended December 31,        
     2011     2010     Change      2011     2010     Change  

Revenues (1)

   $ 30,839      $ 28,247        9 %       $ 91,035      $ 83,231        9 %   

Cost of sales (2) (3)

     29,273        26,786        9             86,313        79,012        9       
  

 

 

   

 

 

      

 

 

   

 

 

   

Gross profit

     1,566        1,461        7             4,722        4,219        12       

Operating expenses (2)

     1,047        965        8             3,135        2,808        12       

Litigation charges (4)

     27        189        (86)            145        213        (32)      
  

 

 

   

 

 

      

 

 

   

 

 

   

Total operating expenses

     1,074        1,154        (7)            3,280        3,021        9       
  

 

 

   

 

 

      

 

 

   

 

 

   

Operating income

     492        307        60             1,442        1,198              20       

Other income (expense), net

     (2     7        (129)            12        19        (37)      

Interest expense

     (64     (53     21             (192     (140     37       
  

 

 

   

 

 

      

 

 

   

 

 

   

Income from continuing operations before income taxes

     426        261        63             1,262        1,077        17       

Income tax expense

     (126     (106     19             (380     (369     3       
  

 

 

   

 

 

      

 

 

   

 

 

   

Income from continuing operations

     300        155        94             882        708        25       

Discontinued operation - gain on sale, net of tax (5)

                   —                    72        —       
  

 

 

   

 

 

      

 

 

   

 

 

   

Net income

   $ 300      $ 155        94           $ 882      $ 780        13       
  

 

 

   

 

 

      

 

 

   

 

 

   

Earnings per common share (6)

             

Diluted

             

Continuing operations

   $ 1.20      $ 0.60        100 %       $ 3.51      $ 2.69        30 %   

Discontinued operation - gain on sale

                   —                    0.27        —       
  

 

 

   

 

 

      

 

 

   

 

 

   

Total

   $ 1.20      $ 0.60            100           $ 3.51      $ 2.96        19       
  

 

 

   

 

 

      

 

 

   

 

 

   

Basic

             

Continuing operations

   $ 1.22      $ 0.61        100 %       $ 3.57      $ 2.73        31 %   

Discontinued operation - gain on sale

                   —                    0.28        —       
  

 

 

   

 

 

      

 

 

   

 

 

   

Total

   $ 1.22      $ 0.61        100           $ 3.57      $ 3.01        19       
  

 

 

   

 

 

      

 

 

   

 

 

   

Shares on which earnings per common share were based

             

Diluted

     251        258        (3)%         252        264        (5)%   

Basic

     246        254        (3)            247        259        (5)      

 

 

(1) Revenues for fiscal year 2011 include the recognition of $23 million of revenue for a disease management contract for which the related expenses were previously recognized as incurred.

 

(2) Technology Solutions segment results for the fiscal year 2012 include a charge of $42 million for a product alignment plan, of which $26 million and $16 million were included in cost of sales and operating expenses.

 

(3) Cost of sales for the first nine months of 2011 includes an asset impairment charge of $72 million in our Technology Solutions segment for capitalized software held for sale and a credit of $51 million in our Distribution Solutions segment representing our share of a settlement of an antitrust class action lawsuit brought against a drug manufacturer.

 

(4) Operating expenses includes charges for the Average Wholesale Price (“AWP”) litigation.

 

(5) In the second quarter of 2011 we sold a Technology Solutions business for $109 million of net sales proceeds. The after-tax gain on sale of $72 million has been recorded as a discontinued operation. Financial operating results for this business were immaterial.

 

(6) Certain computations may reflect rounding adjustments.


Schedule 2A

McKESSON CORPORATION

RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED EARNINGS (NON-GAAP)

(unaudited)

(in millions, except per share amounts)

 

                                  Change  
    Quarter Ended December 31, 2011     Vs. Prior Quarter  
    As Reported
(GAAP)
   

Amortization

of Acquisition-
Related

Intangibles

    Acquisition-
Related
Expenses
    Litigation
Reserve
Adjustments
   

Adjusted

Earnings
(Non-GAAP)

    As
Reported
(GAAP)
   

Adjusted

Earnings

(Non-GAAP)

 
 

 

 

   

 

 

 

Revenues

  $ 30,839      $      $      $      $ 30,839        9 %        9 %   

Gross profit

  $ 1,566      $ 5      $      $      $ 1,571        7            7       

Operating expenses

    (1,074     44        8        27        (995     (7)           9       

Other income (expense), net

    (2                          (2     (129)           (129)      

Interest expense

    (64                          (64     21            49       
 

 

 

     

Income from continuing operations before income taxes

    426        49        8        27        510        63            —       

Income tax expense

    (126     (18     (3     (12     (159     19            (13)      
 

 

 

     

Income from continuing operations

  $ 300      $ 31      $ 5      $ 15      $ 351        94            6       
 

 

 

     

Diluted earnings per common share from continuing operations (1)

  $ 1.20      $ 0.12      $ 0.02      $ 0.06      $ 1.40        100 %        9 %   
 

 

 

     

Diluted weighted average shares

    251        251        251        251        251        (3)%        (3)%   
 

 

 

     
    Quarter Ended December 31, 2010        
    As Reported
(GAAP)
   

Amortization

of Acquisition-
Related

Intangibles

    Acquisition-
Related
Expenses
    Litigation
Reserve
Adjustments
   

Adjusted  

Earnings  
(Non-GAAP)  

             
 

 

 

     

Revenues

  $ 28,247      $      $      $      $ 28,247       

Gross profit

  $ 1,461      $ 4      $      $      $ 1,465       

Operating expenses

    (1,154     24        24        189        (917    

Other income (expense), net

    7                             7       

Interest expense

    (53            10               (43    
 

 

 

     

Income from continuing operations before income taxes

    261        28        34        189        512       

Income tax expense

    (106     (11     (9     (56     (182    
 

 

 

     

Income from continuing operations

  $ 155      $ 17      $ 25      $ 133      $ 330       
 

 

 

     

Diluted earnings per common share from continuing operations (1)

  $ 0.60      $ 0.07      $ 0.10      $ 0.52      $ 1.28       
 

 

 

     

Diluted weighted average shares

    258        258        258        258        258       
 

 

 

     

 

 

(1) Certain computations may reflect rounding adjustments.

Adjusted Earnings (Non-GAAP) Financial Information

Adjusted Earnings represents income from continuing operations, excluding the effects of the following items from the Company’s GAAP financial results, including the related income tax effects:

Amortization of acquisition-related intangibles — Amortization expense of acquired intangible assets purchased in connection with acquisitions by the Company.

Acquisition-related expenses — Transaction and integration expenses that are directly related to acquisitions by the Company. Examples include transaction closing costs, professional service fees, restructuring or severance charges, retention payments, employee relocation expenses, facility or other exit-related expenses, recoveries of acquisition-related expenses or post-closing expenses, or bridge loan fees.

Litigation reserve adjustments — Adjustments to the Company’s reserves for estimated probable losses for its Average Wholesale Price and Securities Litigation matters, as such terms were defined in the Company’s Annual Reports on Form 10-K for the fiscal years ended March 31, 2011 and 2009, respectively.

Income taxes on Adjusted Earnings are calculated in accordance with Accounting Standards Codification 740, “Income Taxes,” which is the same accounting principles used by the Company when presenting its GAAP financial results.

The Company believes the presentation of non-GAAP measures such as Adjusted Earnings provides useful supplemental information to investors with regard to its core operating performance, as well as assists with the comparison of its past financial performance to the Company’s future financial results. Moreover, the Company believes that the presentation of Adjusted Earnings assists investors’ ability to compare its financial results to those of other companies in the same industry. However, the Company’s Adjusted Earnings measure may be defined and calculated differently by other companies in the same industry.

The Company internally uses non-GAAP financial measures such as Adjusted Earnings in connection with its own financial planning and reporting processes. Specifically, Adjusted Earnings serves as one of the measures management utilizes when allocating resources, deploying capital and assessing business performance and employee incentive compensation. Nonetheless, non-GAAP financial results and related measures disclosed by the Company should not be considered a substitute for, nor superior to, financial results and measures as determined or calculated in accordance with GAAP.


Schedule 2B

McKESSON CORPORATION

RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED EARNINGS (NON-GAAP)

(unaudited)

(in millions, except per share amounts)

 

                                   Change  
     Nine Months Ended December 31, 2011     Vs. Prior Period  
     As Reported
(GAAP)
   

Amortization

of Acquisition-
Related

Intangibles

   

Acquisition-

Related

Expenses

    Litigation
Reserve
Adjustments
   

Adjusted

Earnings

(Non-GAAP)

    As
Reported
(GAAP)
   

Adjusted

Earnings

(Non-GAAP)

 
  

 

 

   

 

 

 

Revenues

   $ 91,035      $      $      $      $ 91,035         9 %        9 %   

Gross profit

   $ 4,722      $ 16      $      $      $ 4,738             12            12       

Operating expenses

     (3,280     131        26        145        (2,978)        9            10       

Other income, net

     12                             12         (37)           (37)      

Interest expense

     (192                          (192)        37            48       
  

 

 

     

Income from continuing operations before income taxes

     1,262        147        26        145        1,580         17            12       

Income tax expense

     (380     (56     (9     (53     (498)        3            5       
  

 

 

     

Income from continuing operations

   $ 882      $ 91      $ 17      $ 92      $ 1,082         25            16       
  

 

 

     

Diluted earnings per common share from continuing operations (1)

   $ 3.51      $ 0.36      $ 0.06      $ 0.37      $ 4.30         30 %        21 %   
  

 

 

     

Diluted weighted average shares

     252        252        252        252        252         (5)%        (5)%   
  

 

 

     
     Nine Months Ended December 31, 2010              
     As Reported
(GAAP)
    Amortization
of Acquisition-
Related
Intangibles
    Acquisition-
Related
Expenses
    Litigation
Reserve
Adjustments
    Adjusted    
Earnings    
(Non-GAAP)    
             

Revenues

   $     83,231      $      $      $      $ 83,231        

Gross profit

   $ 4,219      $ 12      $      $      $ 4,231        

Operating expenses

     (3,021     72        24        213        (2,712)       

Other income, net

     19                             19        

Interest expense

     (140            10               (130)       
  

 

 

     

Income from continuing operations before income taxes

     1,077        84        34        213        1,408        

Income tax expense

     (369     (33     (9     (64     (475)       
  

 

 

     

Income from continuing operations

   $ 708      $ 51      $ 25      $ 149      $ 933        
  

 

 

     

Diluted earnings per common share from continuing operations (1)

   $ 2.69      $ 0.19      $ 0.09      $ 0.57      $ 3.54        
  

 

 

     

Diluted weighted average shares

     264        264        264        264        264        
  

 

 

     

 

 

(1) Certain computations may reflect rounding adjustments.


Schedule 3A

McKESSON CORPORATION

RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP)

(unaudited)

(in millions)

 

     Quarter Ended December 31, 2011      Quarter Ended December 31, 2010      Change  
     As
Reported
(GAAP)
     Adjust.      Adjusted
Earnings
(Non-
GAAP)
     As
Reported
(GAAP)
     Adjust.      Adjusted
Earnings
(Non-
GAAP)
     As
Reported
(GAAP)
     Adjusted
Earnings
(Non-
GAAP)
 
  

 

 

    

 

 

    

 

 

 

REVENUES

                       

Distribution Solutions

                       

Direct distribution & services

   $ 21,585            $       $ 21,585            $ 19,408            $       $ 19,408              11 %          11 %    

Sales to customers’ warehouses

     5,198                      5,198              4,731                      4,731              10               10         
  

 

 

    

 

 

       

Total U.S. pharmaceutical distribution & services

     26,783                      26,783              24,139                      24,139              11               11         

Canada pharmaceutical distribution & services

     2,473                      2,473              2,574                      2,574              (4)               (4)         

Medical-Surgical distribution & services

     760                      760              744                      744              2               2         
  

 

 

    

 

 

       

Total Distribution Solutions

     30,016                      30,016              27,457                      27,457              9               9         
  

 

 

    

 

 

       

Technology Solutions

                       

Services (1)

     643                      643              629                      629              2               2         

Software & software systems

     152                      152              135                      135              13               13         

Hardware

     28                      28              26                      26              8               8         
  

 

 

    

 

 

       

Total Technology Solutions

     823                      823              790                      790              4               4         
  

 

 

    

 

 

       

Revenues

   $   30,839            $       $   30,839            $     28,247            $       $     28,247              9               9         
  

 

 

    

 

 

       

GROSS PROFIT

                       

Distribution Solutions

   $ 1,201            $       $ 1,201            $ 1,082            $       $ 1,082              11               11         

Technology Solutions (1) (2)

     365              5         370              379              4         383              (4)               (3)         
  

 

 

    

 

 

       

Gross profit

   $ 1,566            $ 5       $ 1,571            $ 1,461            $ 4       $ 1,465              7               7         
  

 

 

    

 

 

       

OPERATING EXPENSES

                       

Distribution Solutions

   $ (690)           $ 62       $ (628)           $ (797)           $ 226       $ (571)             (13)               10         

Technology Solutions (2)

     (297)             15         (282)             (273)             11         (262)             9               8         

Corporate

     (87)             2         (85)             (84)                     (84)             4               1         
  

 

 

    

 

 

       

Operating expenses

   $ (1,074)           $ 79       $ (995)           $ (1,154)           $ 237       $ (917)             (7)               9         
  

 

 

    

 

 

       

OTHER INCOME (EXPENSE), NET

                       

Distribution Solutions

   $ (1)           $       $ (1)           $ 4            $       $ 4              (125)               (125)         

Technology Solutions

     1                      1              —                      —              —               —         

Corporate

     (2)                     (2)             3                      3              (167)               (167)         
  

 

 

    

 

 

       

Other income (expense), net

   $ (2)           $       $ (2)           $ 7            $       $ 7              (129)               (129)         
  

 

 

    

 

 

       

OPERATING PROFIT

                       

Distribution Solutions

   $ 510            $ 62       $ 572            $ 289            $ 226       $ 515              76               11         

Technology Solutions (1) (2)

     69              20         89              106              15         121              (35)               (26)         
  

 

 

    

 

 

       

Operating profit

     579              82         661              395              241         636              47               4         

Corporate

     (89)             2         (87)             (81)                     (81)             10               7         
  

 

 

    

 

 

       

Income from continuing operations before interest expense and income taxes

   $ 490            $ 84       $ 574            $ 314            $ 241       $ 555              56               3         
  

 

 

    

 

 

       

STATISTICS

                       

Operating profit as a % of revenues

                       

Distribution Solutions

     1.70 %             1.91 %          1.05 %             1.88 %          65 bp         3 bp   

Technology Solutions (1) (2)

     8.38                 10.81              13.42                 15.32              (504)               (451)         

 

 

(1) Revenues and results for the third quarter of fiscal year 2011 include the recognition of $23 million of revenue for a disease management contract for which the related expenses were previously recognized as incurred.

 

(2) For the third quarter of fiscal year 2012, segment results include a charge of $42 million for a product alignment plan, of which $26 million and $16 million were included in cost of sales and operating expenses.


Schedule 3B

McKESSON CORPORATION

RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP)

(unaudited)

(in millions)

 

     Nine Months Ended December 31, 2011      Nine Months Ended December 31, 2010      Change  
     As
Reported
(GAAP)
     Adjust.      Adjusted
Earnings
(Non-
GAAP)
     As
Reported
(GAAP)
     Adjust.      Adjusted
Earnings
(Non-
GAAP)
     As
Reported
(GAAP)
     Adjusted
Earnings
(Non-
GAAP)
 
  

 

 

    

 

 

    

 

 

    

 

 

 

REVENUES

                       

Distribution Solutions

                       

Direct distribution & services

   $ 63,484            $       $ 63,484            $ 57,094            $       $ 57,094              11 %         11 %   

Sales to customers’ warehouses

     14,998                      14,998              14,133                      14,133              6              6        
  

 

 

    

 

 

       

Total U.S. pharmaceutical distribution & services

     78,482                      78,482              71,227                      71,227              10              10        

Canada pharmaceutical distribution & services

     7,739                      7,739              7,485                      7,485              3              3        

Medical-Surgical distribution & services

     2,364                      2,364              2,200                      2,200              7              7        
  

 

 

    

 

 

       

Total Distribution Solutions

     88,585                      88,585              80,912                      80,912              9              9        
  

 

 

    

 

 

       

Technology Solutions

                       

Services (1)

     1,916                      1,916              1,828                      1,828              5              5        

Software & software systems

     449                      449              408                      408              10              10        

Hardware

     85                      85              83                      83              2              2        
  

 

 

    

 

 

       

Total Technology Solutions

     2,450                      2,450              2,319                      2,319              6              6        
  

 

 

    

 

 

       

Revenues

   $ 91,035            $       $ 91,035            $ 83,231            $       $ 83,231              9              9        
  

 

 

    

 

 

       

GROSS PROFIT

                       

Distribution Solutions (3)

   $ 3,590            $ 1       $ 3,591            $ 3,239            $       $ 3,239              11              11        

Technology Solutions (1) (2) (4)

     1,132              15         1,147              980              12         992              16              16        
  

 

 

    

 

 

       

Gross profit

   $ 4,722            $ 16       $ 4,738            $ 4,219            $ 12       $ 4,231              12              12        
  

 

 

    

 

 

       

OPERATING EXPENSES

                       

Distribution Solutions

   $ (2,136)           $ 258       $ (1,878)           $ (1,963)           $ 275       $ (1,688)             9              11        

Technology Solutions (2)

     (857)             42         (815)             (798)             34         (764)             7              7        

Corporate

     (287)             2         (285)             (260)                     (260)             10              10        
  

 

 

    

 

 

       

Operating expenses

   $ (3,280)           $ 302       $ (2,978)           $ (3,021)           $ 309       $ (2,712)             9              10        
  

 

 

    

 

 

       

OTHER INCOME, NET

                       

Distribution Solutions

   $ 8            $       $ 8            $ 9            $       $ 9              (11)             (11)       

Technology Solutions

     2                      2              2                      2              —              —        

Corporate

     2                      2              8                      8              (75)             (75)       
  

 

 

    

 

 

       

Other income, net

   $ 12            $       $ 12            $ 19            $       $ 19              (37)             (37)       
  

 

 

    

 

 

       

OPERATING PROFIT

                       

Distribution Solutions (3)

   $ 1,462            $ 259       $ 1,721            $ 1,285            $ 275       $ 1,560              14              10        

Technology Solutions (1) (2) (4)

     277              57         334              184              46         230              51              45        
  

 

 

    

 

 

       

Operating profit

     1,739              316         2,055              1,469              321         1,790              18              15        

Corporate

     (285)             2         (283)             (252)                     (252)             13              12        
  

 

 

    

 

 

       

Income from continuing operations before interest expense and income taxes

   $ 1,454            $ 318       $ 1,772            $ 1,217            $ 321       $ 1,538              19              15        
  

 

 

    

 

 

       

STATISTICS

                       

Operating profit as a % of revenues

                       

Distribution Solutions (3)

     1.65 %             1.94 %          1.59 %             1.93 %          6 bp         1 bp   

Technology Solutions (1) (2) (4)

     11.31                 13.63              7.93                 9.92              338              371        

 

 

(1) Revenues and results for the first nine months of 2011 include the recognition of $23 million of revenue for a disease management contract for which the related expenses were previously recognized as incurred.

 

(2) For the first nine months of fiscal year 2012, segment results include a charge of $42 million for a product alignment plan, of which $26 million and $16 million were included in cost of sales and operating expenses.

 

(3) Results for the first nine months of fiscal year 2011 include a credit of $51 million representing our share of a settlement of an antitrust class action lawsuit brought against a drug manufacturer.

 

(4) Results for the first nine months of fiscal year 2011 include a $72 million asset impairment charge for capitalized software held for sale.


Schedule 4A

McKESSON CORPORATION

RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP) —

BY ADJUSTMENT TYPE

(unaudited)

(in millions)

 

     Quarter Ended December 31, 2011      Quarter Ended December 31, 2010  
     Distribution
Solutions
     Technology
Solutions
     Corporate
& Interest
Expense
     Total      Distribution
Solutions
     Technology
Solutions
     Corporate
& Interest
Expense
     Total  
  

 

 

    

 

 

 

As Reported (GAAP):

                       

Revenues

   $ 30,016        $ 823        $ —        $   30,839        $ 27,457        $ 790        $ —        $   28,247    

Gross profit

   $ 1,201        $ 365        $ —        $ 1,566        $ 1,082        $ 379        $ —        $ 1,461    

Operating expenses

     (690)         (297)         (87)         (1,074)         (797)         (273)         (84)         (1,154)   

Other income (expense), net

     (1)                 (2)         (2)                 —                    
  

 

 

    

 

 

 

Income from continuing operations before interest expense and income taxes

     510          69          (89)         490          289          106          (81)         314    

Interest expense

     —          —          (64)         (64)         —          —          (53)         (53)   
  

 

 

    

 

 

 

Income from continuing operations before income taxes

   $ 510        $ 69        $ (153)       $ 426        $ 289        $ 106        $ (134)       $ 261    
  

 

 

    

 

 

 

Pre-Tax Adjustments:

                       

Gross profit

   $ —        $       $ —        $       $ —        $       $ —        $   

Operating expenses

     31          13          —          44          13          11          —          24    
  

 

 

    

 

 

 

Amortization of acquisition-related intangibles

     31          18          —          49          13          15          —          28    

Operating expenses

                                     24          —          —          24    

Interest expense

     —          —          —          —          —          —          10          10    
  

 

 

    

 

 

 

Acquisition-related expenses

                                     24          —          10          34    

Operating expenses - Litigation reserve adjustments

     27          —          —          27          189          —          —          189    
  

 

 

    

 

 

 

Total pre-tax adjustments

   $ 62        $ 20        $       $ 84        $ 226        $ 15        $ 10        $ 251    
  

 

 

    

 

 

 

Adjusted Earnings (Non-GAAP):

                       

Revenues

   $ 30,016        $ 823        $ —        $ 30,839        $ 27,457        $ 790        $ —        $ 28,247    

Gross profit

   $ 1,201        $ 370        $ —        $ 1,571        $ 1,082        $ 383        $ —        $ 1,465    

Operating expenses

     (628)         (282)         (85)         (995)         (571)         (262)         (84)         (917)   

Other income (expense), net

     (1)                 (2)         (2)                 —                    
  

 

 

    

 

 

 

Income from continuing operations before interest expense and income taxes

     572          89          (87)         574          515          121          (81)         555    

Interest expense

     —          —          (64)         (64)         —          —          (43)         (43)   
  

 

 

    

 

 

 

Income from continuing operations before income taxes

   $ 572        $ 89        $ (151)       $ 510        $ 515        $ 121        $ (124)       $ 512    
  

 

 

    

 

 

 


Schedule 4B

McKESSON CORPORATION

RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP) —

BY ADJUSTMENT TYPE

(unaudited)

(in millions)

 

     Nine Months Ended December 31, 2011      Nine Months Ended December 31, 2010  
     Distribution
Solutions
    Technology
Solutions
    Corporate
& Interest
Expense
    Total      Distribution
Solutions
    Technology
Solutions
    Corporate
& Interest
Expense
    Total  
  

 

 

    

 

 

 

As Reported (GAAP):

                 

Revenues

   $     88,585      $     2,450      $      $     91,035         $ 80,912      $ 2,319      $      $   83,231    

Gross profit

   $ 3,590      $ 1,132      $      $ 4,722         $ 3,239      $ 980      $      $ 4,219    

Operating expenses

     (2,136     (857     (287     (3,280)          (1,963     (798     (260     (3,021)   

Other income, net

     8        2        2        12           9        2        8        19    
  

 

 

    

 

 

 

Income from continuing operations before interest expense and income taxes

     1,462        277        (285     1,454           1,285        184        (252     1,217    

Interest expense

                   (192     (192)                        (140     (140)   
  

 

 

    

 

 

 

Income from continuing operations before income taxes

   $ 1,462      $ 277      $ (477   $ 1,262         $ 1,285      $ 184      $ (392   $ 1,077    
  

 

 

    

 

 

 

Pre-Tax Adjustments:

                 

Gross profit

   $ 1      $ 15      $      $ 16         $      $ 12      $      $ 12    

Operating expenses

     93        38               131           38        34               72    
  

 

 

    

 

 

 

Amortization of acquisition-related intangibles

     94        53               147           38        46               84    

Operating expenses

     20        4        2        26           24                      24    

Interest expense

                          —                         10        10    
  

 

 

    

 

 

 

Acquisition-related expenses

     20        4        2        26           24               10        34    

Operating expenses - Litigation reserve adjustments

     145                      145           213                      213    
  

 

 

    

 

 

 

Total pre-tax adjustments

   $ 259      $ 57      $ 2      $ 318         $ 275      $ 46      $ 10      $ 331    
  

 

 

    

 

 

 

Adjusted Earnings (Non-GAAP):

                 

Revenues

   $ 88,585      $ 2,450      $      $ 91,035         $ 80,912      $ 2,319      $      $ 83,231    

Gross profit

   $ 3,591      $ 1,147      $      $ 4,738         $ 3,239      $ 992      $      $ 4,231    

Operating expenses

     (1,878     (815     (285     (2,978)          (1,688     (764     (260     (2,712)   

Other income, net

     8        2        2        12           9        2        8        19    
  

 

 

    

 

 

 

Income from continuing operations before interest expense and income taxes

     1,721        334        (283     1,772           1,560        230        (252     1,538    

Interest expense

                   (192     (192)                        (130     (130)   
  

 

 

    

 

 

 

Income from continuing operations before income taxes

   $ 1,721      $ 334      $ (475   $ 1,580         $ 1,560      $ 230      $ (382   $ 1,408    
  

 

 

    

 

 

 


Schedule 5

McKESSON CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

(in millions)

 

December 31, December 31,
     December 31,
2011
     March 31,
2011
 

ASSETS

     

Current Assets

     

Cash and cash equivalents

   $ 4,191       $ 3,612   

Receivables, net

     9,673         9,187   

Inventories, net

     10,376         9,225   

Prepaid expenses and other

     329         333   
  

 

 

    

 

 

 

Total Current Assets

     24,569         22,357   

Property, Plant and Equipment, Net

     1,015         991   

Goodwill

     4,497         4,364   

Intangible Assets, Net

     1,341         1,456   

Other Assets

     1,735         1,718   
  

 

 

    

 

 

 

Total Assets

   $ 33,157       $ 30,886   
  

 

 

    

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

     

Current Liabilities

     

Drafts and accounts payable

   $ 15,677       $ 14,090   

Deferred revenue

     1,471         1,321   

Deferred tax liabilities

     1,038         1,037   

Current portion of long-term debt

     409         417   

Other accrued liabilities

     2,120         1,861   
  

 

 

    

 

 

 

Total Current Liabilities

     20,715         18,726   

Long-Term Debt

     3,578         3,587   

Other Noncurrent Liabilities

     1,408         1,353   

Stockholders’ Equity

     7,456         7,220   
  

 

 

    

 

 

 

Total Liabilities and Stockholders’ Equity

   $ 33,157       $ 30,886   
  

 

 

    

 

 

 


Schedule 6

McKESSON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in millions)

 

     Nine Months Ended December 31,  
     2011      2010  

OPERATING ACTIVITIES

     

Net income

   $ 882         $ 780     

Discontinued operation — gain on sale, net of tax

     —           (72)    

Adjustments to reconcile to net cash provided by operating activities:

     

Depreciation and amortization

     408           352     

Asset impairment charge — capitalized software held for sale

     —           72     

Share-based compensation expense

     113           99     

Other non-cash items

     102           58     

Changes in operating assets and liabilities, net of acquisitions:

     

Receivables

     (575)          (198)    

Inventories

     (1,200)          22     

Drafts and accounts payable

     1,636           52     

Deferred revenue

     122           82     

Litigation charges

     145           213     

Litigation settlement payments

     (26)          (26)    

Deferred tax benefit on litigation charges

     (42)          (56)    

Other

     151           (40)    
  

 

 

    

 

 

 

Net cash provided by operating activities

     1,716           1,338     
  

 

 

    

 

 

 

INVESTING ACTIVITIES

     

Property acquisitions

     (170)          (157)    

Capitalized software expenditures

     (137)          (111)    

Acquisitions, less cash and cash equivalents acquired

     (204)          (292)    

Proceeds from sale of business

     —           109     

Other

     81           (15)    
  

 

 

    

 

 

 

Net cash used in investing activities

     (430)          (466)    
  

 

 

    

 

 

 

FINANCING ACTIVITIES

     

Repayments of debt

     (23)          —     

Common stock repurchases, including shares surrendered for tax withholding

     (672)          (1,548)    

Common stock Issuances

     122           238     

Dividends paid

     (146)          (126)    

Other

     22           40     
  

 

 

    

 

 

 

Net cash used in financing activities

     (697)          (1,396)    
  

 

 

    

 

 

 

Effect of exchange rate changes on cash and cash equivalents

     (10)          6     
  

 

 

    

 

 

 

Net increase (decrease) in cash and cash equivalents

     579           (518)    

Cash and cash equivalents at beginning of period

     3,612           3,731     
  

 

 

    

 

 

 

Cash and cash equivalents at end of period

   $ 4,191         $ 3,213